GlassScriptPhysician profile
Rachael Doster
NPI 1316624216
$3,589.87
in general payments reported to CMS, 2019-2025
28 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $639 · 2024: $1,555 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,589.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $640.67 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $353.38 | 2024-2025 | Evenity, Prolia |
| Abbvie INC. | $327.41 | 2023-2025 | |
| Novo Nordisk INC | $239.55 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Cequr Corporation | $227.89 | 2023-2025 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $183.83 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $162.05 | 2023-2024 | Omnipod |
| Medtronic, INC. | $144.65 | 2023-2025 | Minimed 780g |
| Ascensia Diabetes Care US INC. | $142.62 | 2024 | |
| Corcept Therapeutics | $134.04 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $110.98 | 2023-2025 | |
| Mannkind Corporation | $107.72 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $102.04 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Exeltis, USA INC. | $97.87 | 2023-2025 | Slynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.90 | 2023-2024 | Synjardy, Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $63.09 | 2023-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $62.72 | 2024-2025 | Xyosted |
| Radius Health, INC. | $59.62 | 2023-2025 | Tymlos |
| Tolmar, INC. | $57.38 | 2024-2025 | Jatenzo |
| Sequel Med Tech, LLC | $54.92 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $45.40 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $36.56 | 2023-2025 | |
| Dexcom, INC. | $33.72 | 2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $32.41 | 2024-2025 | Tirosint, Licart, Flector |
| Ani Pharmaceuticals, INC. | $25.33 | 2023 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $21.35 | 2025 | Veozah |
| Nevro Corp. | $17.36 | 2023 | Senza |
| Amphastar Pharmaceuticals, INC. | $16.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Doster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.